Long Noncoding RNAs Act as Novel Biomarkers for Hepatocellular Carcinoma: Progress and Prospects

Table 2

Dysregulated lncRNAs in serum of HCC patients.

Name	Dysregulation	Samples (HCC/Control)	Description	Area under the ROC curve	Reference
HULC	Up	30/20	Increase with Edmondson grade, detected more frequently in HBV+ HCC patients	Not reported	[35]
	Up	90/77	Correlated with tumor size and tumor capsule	0.78	[36]
Linc00152	Up	90/77	Related to differentiation grade, tumor size, TNM stage and tumor capsule	0.85	[36]
MALAT1	Up	88/79	Significantly lower in HCC patients with hepatitis B infection and significantly higher in patients with liver damage B or liver cirrhosis	0.66	[41]
HEIH	Up	179/179	Positively related to TNM stage and the risk of HCC	0.681	[39]
PVT1	Up	71/64	Associated with clinical parameters including tumor size, BCLC stage and serum bilirubin	0.764 (combined with uc002mbe.2)	[43]
uc002mbe.2	Up	71/64	Same with PVT1	0.764 (combined with PVT1)	[43]
UCA1	Up	82/78	Associated with HCV-antibodies positive patients and Child-Pugh score	0.861	[40]
WRAP53	Up	82/78	Same with UCA1	0.896	[40]
uc003wbd	Up	137/138	Also significantly highly expressed in HBV patients	0.86	[37]
AF085935	Up	137/138	Same with uc003wbd	0.96	[37]
uc001ncr	Up	232/452	High diagnostic performance in patients with AFP <400 ng/ml and early HCC	0.8859	[42]
AX800134	Up	232/452	Same with uc001ncr	0.9251	[42]
RP11-160H22.5	Up	217/250	Decrease after operation	0.601	[38]
XLOC_014172	Up	217/250	Higher expression in HCC patients with metastasis	0.866	[38]
LOC149086	Up	217/250	Same with XLOC_014172	0.759	[38]